natgillin/translations-raw huggingface dataset:
Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic GvHD when compared with bone marrow transplantation.
Trenutni podatki kažejo, da so lahko imunološka medsebojna delovanja med presajenimi alogenskimi matičnimi celicami iz periferne krvi in prejemnikom v primerjavi s presaditvijo kostnega mozga povezane z večjim tveganjem za akutno in kronično reakcijo presadka proti gostitelju (GvHD).
Current data on catumaxomab derived from the pivotal study show that only 5.6% of patients (7/124 patients) were HAMA positive before the 4th infusion.
Razpoložljivi podatki o katumaksomabu, pridobljeni iz osrednje študije, kažejo, da je bilo le 5,6 % bolnikov (7/124 bolnikov) pozitivnih na HAMA pred
Current evidence is derived from one randomised controlled trial of 2 months duration and an open extension trial of 6 month duration in addition to long-term outcome collected after end of MDR-TB treatment (see section 5.1).
Trenutni dokazi so pridobljeni iz enega randomiziranega nadzorovanega preskušanja, ki je trajalo 2 meseca, in odprtega podaljšanega preskušanja, ki je trajalo 6 mesecev, poleg dolgoročnih rezultatov, zbranih po koncu zdravljenja MDR-TB (glejte poglavje 5.1).
Current or past use of medicinal products with alpha1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery.
Očesni kirurg mora biti pred operacijo seznanjen, če bolnik jemlje oziroma je jemal zdravila z antagonističnim učinkom na receptorje alfa-1a.
Current or past use of medicines with alpha1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery.
Očesni kirurg mora biti pred operacijo seznanjen, če bolnik jemlje oziroma je jemal zdravila z antagonističnim učinkom na receptorje alfa-1a.
Current or previous venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism.
Prisotna ali predhodna venska trombembolija (VTE – venous thromboembolic events), vključno z globoko vensko trombozo in pljučno embolijo.
Current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).
Trenutna huda depresija in/ali samomorilne misli (glejte poglavji 4.4 in 4.8).
Current treatment guidelines should be consulted as to whether a liver biopsy is needed prior to commencing treatment.
Pri odločanju, ali je pred začetkom zdravljenja potrebna jetrna biopsija, upoštevajte veljavne terapevtske smernice.
Currently available data are described in section 4.8 and 5.1, but no recommendation on a posology can be made.
Dosegljivi podatki so navedeni v poglavjih 4.8 in 5.1, vendar priporočila o odmerjanju še niso določena.
Currently available data are described in section 4.8 but no recommendation on a posology can be made.
Trenutno razpoložljivi podatki so opisani v poglavju 4.8, vendar priporočil za odmerjanje ni mogoče dati.
Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on posology can be made.
Trenutno razpoložljivi podatki so opisani v poglavjih 4.8, 5.1 in 5.2, vendar priporočil o odmerjanju ni mogoče dati.
Currently available data are described in section 4.8, 5.1 and 5.2, but no recommendation on a posology can be made.
Trenutno razpoložljivi podatki so opisani v poglavjih 4.8, 5.1 in 5.2, vendar ni mogoče dati priporočil o odmerjanju.
Currently available data are described in section 4.8, 5.1 and 5.2. Method of administration
Podatki, ki so trenutno na voljo, so opisani v poglavjih 4.8, 5.1 in 5.2. Način uporabe
Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
Trenutno dosegljivi podatki so navedeni v poglavjih 5.1 in 5.2, toda priporočila o odmerjanju ni mogoče podati.
Currently available data are described in section 5.2 but no recommendation on a posology can be made
Trenutno razpoložljivi podatki so opisani v poglavju 5.2, vendar priporočil o odmerjanju ni mogoče dati.
Currently available data are described in section 5.2 but no recommendation on a posology can be made.
Podatki, ki so trenutno na voljo, so opisani v poglavju 5.2, vendar ne moremo podati priporočila o odmerjanju.
Currently available data are described in section 5.2 but no recommendation on a posology can be made.
Trenutno razpoložljivi podatki so opisani v poglavju 5.2, vendar priporočil za odmerjanje ni mogoče podati.
Currently available data are described in section 5.2, but no recommendation on a posology can be made.
Podatki, ki so trenutno na voljo, so opisani v poglavju 5.2, a priporočil za odmerjanje ni mogoče dati.
Currently available data are described in section 5.2.
Trenutno razpoložljivi podatki so opisani v poglavju 5.2.
Currently available data are described in section and 5.1 but no recommendation on a posology can be made.
Trenutno razpoložljivi podatki so opisani v poglavju 5.1, vendar priporočil o odmerjanju ni mogoče dati.
Currently available data are described in sections 4.4 and 5.1 but no recommendation on a posology can be made.
Na podlagi zadnjih dostopnih podatkov, ki so opisani v poglavjih 4.4 in 5.1 ni mogoče priporočati uporabe.
Currently available data are described in sections 4.8 and 5.1. AZOPT is not recommended for use in infants, children and adolescents.
Trenutno razpoložljivi podatki so opisani v poglavju 4.8 in 5.1. Uporaba zdravila AZOPT pri dojenčkih, otrocih in mladostnikih ni priporočljiva.
Currently available data are described in sections 5.1 and 5.2 but no recommendation on a posology can be made.
Podatki, ki so trenutno na voljo, so opisani v poglavjih 5.1 in 5.2, toda priporočil za odmerjanje ni mogoče dati.
Currently available data are not sufficient to establish the efficacy of Menveo in children under 2 years of age.
Trenutno razpoložljivi podatki ne zadostujejo za dokaz učinkovitosti cepiva Menveo pri otrocih, mlajših od 2 let.
Currently available data in adolescents from 12 to 17 years are described in sections 4.8, 5.1 and 5.2, but no recommendation on a posology can be made.
Trenutno razpoložljivi podatki za mladostnike, stare od 12 do 17 let, so opisani v poglavjih 4.8, 5.1 in 5.2, vendar priporočil o odmerjanju ni mogoče dati.
Currently available limited data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.
Trenutno razpoložljivi omejeni podatki so opisani v poglavjih 4.8, 5.1 in 5.2, vendar priporočil o odmerjanju ni mogoče dati.
Currently available pharmacokinetic data are described in section 5.2 but no recommendation on a posology can be made in children younger than 6 years.
Trenutno razpoložljivi farmakokinetični podatki so opisani v poglavju 5.2, vendar priporočil o odmerjanju za otroke, mlajše od 6 let, ni mogoče dati.
Currently available pharmacokinetic data are described in section 5.2. Lenalidomide has been used in clinical trials in multiple myeloma patients up to 91 years of age and in mantle cell lymphoma patients up to 88 years of age (see section 5.1).
Farmakokinetični podatki, ki so trenutno na voljo, so opisani v poglavju 5.2. Lenalidomid so v kliničnih preskušanjih uporabljali pri bolnikih z diseminiranim plazmocitomom, starih do 91 let, in pri bolnikih z limfomom plaščnih celic, starih do 88 let (glejte poglavje 5.1).
Currently available pharmacokinetic data are described in section 5.2. Lenalidomide has been used in clinical trials in multiple myeloma patients up to 91 years of age, in myelodysplastic syndromes patients up to 95 years of age and in mantle cell lymphoma patients up to 88 years of age (see section 5.1).
Farmakokinetični podatki, ki so trenutno na voljo, so opisani v poglavju 5.2. Lenalidomid so v kliničnih preskušanjih uporabljali pri bolnikih z diseminiranim plazmocitomom, starih do 91 let, pri bolnikih z mielodisplastičnimi sindromi, starih do 95 let, in pri bolnikih z limfomom plaščnih celic, starih do 88 let (glejte poglavje 5.1).
currently have a stomach ulcer, a bleeding disorder (such as haemophilia) or problems with nose bleeds. take medicines for erectile dysfunction.
imate trenutno razjedo na želodcu, ste nagnjeni h krvavitvam (npr. imate hemofilijo) ali imate težave s krvavitvami iz nosu. jemljete zdravila za zdravljenje erektilne disfunkcije.
Currently in clinical practice, sirolimus whole blood concentrations are being measured by both chromatographic and immunoassay methodologies.
Trenutno se v klinični praksi koncentracija sirolimusa v polni krvi meri tako s kromatografskimi kot z imunološkimi metodami.
currently receiving treatment with Sylvant.
z zdravilom Sylvant ali se zdravijo z zdravilom Sylvant.
currently suffer from inflammatory arthritis or inflammatory joint disease of the knee
če imate trenutno vnetni artritis ali vnetno bolezen kolenskega sklepa;
Currently there are no data on the use of Trizivir in heavily pre-treated patients, patients failing on other therapies or patients with advanced disease (CD4 cells  50 cells/mm3).
Trenutno ni podatkov o uporabnosti zdravila Trizivir pri bolnikih, ki so bili predhodno intenzivno zdravljeni, pri bolnikih pri katerih so bila druga zdravljenja neuspešna, ali pri bolnikih z napredovalo boleznijo (CD4 celice  50 celic/mm3).
Currently there is no experience of overdose with the use of Colobreathe.
Trenutno ni izkušenj s prevelikim odmerjanjem pri uporabi zdravila Colobreathe.
Currently there is only evidence of the efficacy of the vaccine against challenge with B. canis.
Dokazana je samo učinkovitost cepiva proti B. canis.
Currently, no clinical data are available in neonates.
Trenutno niso na voljo klinični podatki za novorojenčke.
Currently, no data on sperm development in healthy adult males and adult males with mild erectile dysfunction are available.
Trenutno ni na voljo podatkov o razvoju sperme pri zdravih odraslih moških in odraslih moških z blago erektilno disfunkcijo.
Currently, no data on spermatogenesis on healthy adult males and adult males with mild ED are available.
Trenutno ni na voljo podatkov o spermatogenezi pri zdravih odraslih moških in odraslih moških z blago erektilno disfunkcijo.
Currently, the efficacy and safety data are too limited to allow specific recommendations for use of sirolimus in Black recipients.
Trenutno je premalo podatkov o učinkovitosti in varnosti zdravila, da bi dovoljevali specifična priporočila o uporabi sirolimusa pri osebah črne rase.
Currently, there is no clinical experience to support the use of desirudin beyond 12 days.
Trenutno ni kliničnih izkušenj, ki bi govorile v prid več kot 12-dnevni uporabi desirudina.
Currently, there is no clinical experience to support the use of Revasc beyond 12 days.
Trenutno ni kliničnih izkušenj, ki bi govorile v prid več kot 12-dnevni uporabi Revasca.
Curvularia spp. and Sporothrix spp.
Curvularia spp. in Sporothrix spp.
CuSCC was very commonly reported and was most commonly treated by local excision.
Zelo pogosto je bil opisan ploščatocelični karcinom kože, ki so ga večinoma zdravili z lokalno ekscizijo.
Cushing-like symptoms, stria, ecchymoses, acne and hirsutism, impaired wound healing.
Simptomi, podobi Cushingovemu sindromu, strije, ekhimoze, akne in hirsutizem, upočasnjeno celjenje ran.
Cushingoid
bolezen, podobna Cushingovi
cushingoid
kušingoid
Cushing´s syndrome, adrenal suppression, growth retardation, decrease in bone mineral density
Cushingov sindrom, supresija nadledvične žleze, upočasnitev rasti zmanjšanje kostne mineralne gostote
Cushing’s disease
Cushingova bolezen
Cushing’s disease (a hormone disorder where the body produces too much of the hormone cortisol)
Cushingovo bolezen (hormonsko motnjo, pri kateri telo proizvaja preveč hormona kortizola);
Cushing’s disease and acromegaly are both caused by tumours of the pituitary gland (a gland located at the base of the brain).
Cushingovo bolezen in akromegalijo povzročajo tumorji hipofize (žleze, ki se nahaja na možganskem dnu).
Cushing’s disease is caused by an enlargement in the pituitary gland (a gland at the base of the brain) called a pituitary adenoma.
Cushingovo bolezen povzroča povečanje hipofize (žleze na spodnji strani možganov), kar imenujemo adenom hipofize.
Cushing’s disease patients with poor glycaemic control (as defined by HbA1c values >8% while receiving antidiabetic therapy) may be at higher risk of developing severe hyperglycaemia and associated complications (e.g. ketoacidosis).
Bolniki, ki imajo Cushingovo bolezen in slabo urejeno sladkorno bolezen (opredeljeno kot vrednost HbA1c >8 % ob antidiabetičnem zdravljenju), imajo lahko povečano tveganje za hudo hiperglikemijo in z njo povezane zaplete (npr. ketoacidozo).
Cushing’s syndrome has been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide (see section 4.4 and 4.5).
Pri bolnikih, ki so prejemali ritonavir in inhalacijsko ali intranazalno uporabljen flutikazon propionat, so poročali o Cushingovem sindromu; ta se lahko pojavi tudi pri uporabi drugih kortikosteroidov, ki se presnavljajo preko poti P450 3A, npr. budenozid (glejte poglavji 4.4 in 4.5).
Cushing’s syndrome has been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide (see section 4.4 and 4.5).
Pri bolnikih, ki so prejemali ritonavir in inhalacijsko ali intranazalno uporabljen flutikazon propionat, so poročali o Cushingovem sindromu; ta se lahko pojavi tudi pri uporabi drugihkortikosteroidov, ki se presnavljajo preko poti P450 3A, npr. budenozid (glejte poglavji 4.4 in 4.5).
Cushing’s syndrome is a disease characterised by an excess production of the hormone cortisol by the adrenal glands, two glands situated above the kidneys.
Cushingov sindrom je bolezen, pri kateri nadledvične žleze (dve žlezi, ki se nahajata nad ledvicami) tvorita prekomerne količine hormona kortizola.
Cushing’s syndrome is caused by overproduction of a hormone called cortisol which is produced by the adrenal glands.
Cushingov sindrom povzroča čezmerna tvorba hormona, imenovanega kortizol, ki ga proizvaja nadledvična žleza.
Cushing’s syndrome, i.e. weight gain of the trunk and face, excessive sweating, stretch marks, visible swollen capillaries (small blood vessels) and dryness of the skin, growth of extra facial hair (especially in women) and thinning of the hair;
Cushingov sindrom, tj. povečanje mase trupa in obraza, čezmerno potenje, strije, vidne povečane kapilare (majhne žilice) in suha koža, povečana poraščenost obraza (zlasti pri ženskah) in tanjšanje las;
Cut off the top of each sachet with scissors
S škarjami odrežite vrh posamezne vrečice.
Cut the strips as described below:
Razrežite trakova kot opisano spodaj:
Cut-off date
Presečni datum
Cut-off dates
Datumi, do katerih so zbirali podatke
Cutaneous application of a small pea size amount of medicinal product to each of the five areas of the face: forehead, chin, nose, each cheek.
Dermalni nanos majhne količine zdravila v velikosti graha na vsakega od petih predelov obraza (tj. na čelo, brado, nos, vsako lice).
Cutaneous hypersensitivity (e.g.
kožna preobčutljivost (npr.
Cutaneous hypersensitivity, skin rash
preobčutljivostna kožna reakcija, kožni izpuščaj
Cutaneous lesions Subcutaneous lesions Nodal lesions
Kožne spremembe Podkožne spremembe Nodalne spremembe
Cutaneous lupus
eritematozni lupus s
cutaneous lupus erythemato sus* ephelides*, lentigo*
kožni eritematozni lupus*, efelide*, lentigo
cutaneous lupus erythemato sus*, ephelides*, lentigo*
kožni eritematozni lupus*, efelide*, lentigo
Cutaneous lupus erythematosus
kožni eritematozni eritem
Cutaneous lupus erythematosus (rare), Severe skin reactions such as Steven-Johnson Syndrome and toxic Epidermal Necrolysis (very rare) (see section 4.4)
eritematozni lupus s spremembami na koži (redki), hude kožne reakcije, kot sta Stevens- Johnsonov sindrom in toksična epidermalna nekroliza (zelo redki) (glejte poglavje 4.4)
Cutaneous lupus erythematosus (rare), Severe skin reactions such as Stevens- Johnson Syndrome and toxic Epidermal Necrolysis (very rare) (see section 4.4.)
eritematozni lupus s spremembami na koži (redki), hude kožne reakcije, kot sta Stevens- Johnsonov sindrom in toksična epidermalna nekroliza (zelo redki) (glejte poglavje 4.4)
Cutaneous lupus erythematosus (rare), Severe skin reactions such as Stevens-Johnson Syndrome and toxic Epidermal Necrolysis (vary rare) (see section 4.4)
eritematozni lupus s spremembami na koži (redki), hude kožne reakcije, kot sta Stevens- Johnsonov sindrom in toksična epidermalna nekroliza (zelo redki) (glejte poglavje 4.4
Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus
reakcije podobne kožnemu eritematoznemu lupusu, reaktivacija kožnega eritematoznega lupusa
Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, vasculitis necrotising and toxic epidermal necrolysis
reakcije podobne kožnemu eritematoznemu lupusu, reaktivacija kožnega eritematoznega lupusa, nekrotizirajoči vaskulitis in toksična epidermalna nekroliza
Cutaneous lupus erythematosus-like reactionsh, reactivation of cutaneous lupus erythematosush, vasculitis necrotising and toxic epidermal necrolysish
reakcije podobne kožnemu eritematoznemu lupusuh, reaktivacija kožnega eritematoznega lupusah, nekrotizirajoči vaskulitis in toksična epidermalna nekrolizah
Cutaneous patch
dermalni obliž
Cutaneous patch.
dermalni obliž
Cutaneous reactions
Stomatitis/mukozitis
Cutaneous sarcoidosis
kožna sarkidoza
Cutaneous soft tissue haemorrhage
kožna krvavitev v mehkem tkivu
Cutaneous spray, solution
dermalno pršilo, raztopina
Cutaneous spray, solution
dermalno pršilo, raztopina 6,5 ml
Cutaneous spray, solution.
Dermalno pršilo , raztopina.
Cutaneous spray, solution.
Razpršilo za kožo, raztopina.
Cutaneous squamous cell carcinoma
Ploščatocelični karcinom kože
Cutaneous squamous cell carcinoma (cuSCC)
Ploščatocelični karcinom kože
Cutaneous squamous cell carcinoma (d) (cuSCC)
Ploščatocelični karcinom kože (d)
Cutaneous squamous cell carcinoma has been reported with a lower frequency in the Cotellic plus vemurafenib arm vs placebo plus vemurafenib arm (all Grade: 3% vs 13%).
Pogostnost ploščatoceličnega karcinoma kože je bila v skupini z zdravilom Cotellic in vemurafenibom manjša kot v skupini s placebom in vemurafenibom (vse stopnje: 3 % v primerjavi s 13 %).
Cutaneous squamous cell carcinoma, keratoacanthoma and hyperkeratosis
Ploščatocelični karcinom kože, keratoakantom in hiperkeratoza
Cutaneous squamous cell carcinomab
ploščatocelični karcinom kožeb
Cutaneous squamous cell carcinomas (including those classified as keratoacanthoma or mixed keratoacanthoma subtype) occurred in 9% of patients treated with dabrafenib monotherapy in the integrated safety population and 3% of patients treated with dabrafenib in combination with trametinib in MEK115306.
Ploščatocelični karcinomi kože (vključno s spremembami, prepoznanimi kot keratoakantom ali mešani keratoakantomski podtip) so se v skupni varnostni populaciji pojavili pri 9 % bolnikov, zdravljenih z dabrafenibom v monoterapiji, in pri 3 % bolnikov, zdravljenih z dabrafenibom v kombinaciji s trametinibom v študiji MEK115306.
Cutaneous use
Perkutana uporaba
Cutaneous use
Za dermalno uporabo
Cutaneous use
Za zunanjo uporabo
Cutaneous use only
Samo za dermalno uporabo
Cutaneous use only.
Samo za dermalno uporabo
Cutaneous use.
Dajanje na kožo in kožne tvorbe.
Cutaneous use.
dermalna uporaba
Cutaneous use.
Uporaba na koži.
Cutaneous use.
Za porabo na koži.
Cutaneous vasculitis
Kutani vaskulitis
Cutaneous vasculitis
modricam
Cutaneous vasculitis Alopecia
kožni vaskulitis alopecija
cutaneous vasculitis*,†
kožni vaskulitis *,
cutaneous vasculitis1)
kožni vaskulitis1)
Cutaneous vasculitisa
bolečine v prsiha
Cutaneous vasculitisa
kožni vaskulitisa
Cutoff date: 03 June 2011. b Assessed by independent radiology review according to Response Evaluation Criteria in Solid Tumours (RECIST). c One-sided p-value from a log-rank test of treatment stratified by ECOG performance status and prior therapy. d Cutoff date: 01 November 2011. e Cutoff date: 31 August 2010. f Risk ratio is used for ORR.
Presečni datum: 3. junij 2011. b Ocenjeno z neodvisnim radiološkim preverjanjem skladno z merili za ocenjevanje odziva pri solidnih tumorjih (RECIST - Response Evaluation Criteria in Solid Tumours). c Enostranska vrednost p, dobljena iz log-rank testa zdravljenja, stratificirana po stanju zmogljivosti po ECOG in predhodnem zdravljenju. d Presečni datum: 1. november 2011. e Presečni datum: 31. avgust 2010. f Za ORR se uporablja razmerje tveganja.
CV Death
CV smrt
CV death
srčno-žilnega vzroka
CV death**
kardiovaskularna smrt
CV death, MI (excl. silent MI) or stroke
KV smrt, MI (izklj. nemi MI) ali možganska kap
CV death, nonfatal MI, or nonfatal stroke
CV smrt, ne-smrtni MI ali ne-smrtna možganska kap
CV death, total MI, stroke, SRI, RI, TIA, or other ATEc
KV smrt, vsi MI, možganska kap, RPI, PI, TIA ali drugi ATDc
CV: within-patient coefficient of variation in % SS: Steady State
CV: intraindividualni koeficient spremenljivosti v % SS: stanje dinamičnega ravnovesja
CV=coefficient of variation Gender:
KV=koeficient variacije Spol:
CVdeath, non-fatal MI, 406 (13.4%) 399 (13.2%) 1.02 [0.89, 1.17]
Srčno-žilna smrt, MI brez 406 (13,4 %) 399 (13,2 %) 1,02 [0,89; 1,17]
CVMP grounds for a further renewal:
Razlogi CVMP-ja za nadaljnje podaljšanje:
CVMP grounds for a further renewal: European Medicines Agency reflection paper on criteria for requiring one additional five year renewal (EMEA/CVMP/430630/2006).
Podlaga Odbora za zdravila za uporabo v veterinarski medicini (CVMP) za dodatno podaljšanje: študija Evropske agencije za zdravila (EMA) o merilih za zahtevo enega dodatnega petletnega podaljšanja (EMEA/CVMP/430630/2006).
CVMP recommended that Quadrisol should be given a marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom Quadrisol.
CVVH ≤ 30 ml/min 250 mg every 12 hours 4 hours ≤ 1 mg/l
CVVH ≤ 30 ml/min 250 mg na 12 ur 4 ure ≤ 1 mg/l
CVVHDF 5-30 ml/min 500 mg every 12 hours 4 hours ≤ 1 mg/l CRRT: continuous renal replacement therapy; CVVH: continuous venovenous haemofiltration; CVVHDF: continuous venovenous haemodiafiltration; MIC: minimum inhibitory concentration
CVVHDF 5-30 ml/min 500 mg na 12 ur 4 ure ≤ 1 mg/l CRRT (continuous renal replacement therapy): kontinuirano nadomestno zdravljenje končne ledvične odpovedi; CVVH (continuous venovenous haemofiltration): kontinuirana veno-venska hemofiltracija; CVVHDF (continuous venovenous haemodiafiltration): kontinuirana veno-venska hemodiafiltracija; MIC (minimum inhibitory concentration): minimalna inhibitorna koncentracija.
CVVHDF < 5 ml/min 250 mg every 12 hours 4 hours ≤ 1 mg/l
CVVHDF < 5 ml/min 250 mg na 12 ur 4 ure ≤ 1 mg/l
CXCR4 or dual/mixed tropic virus not detected) as determined by an adequately validated and sensitive detection method (see sections 4.1, 4.2 and 5.1).
4.2 in 5.1) ugotovljen CCR5-tropni HIV-1 (tj. ni odkrit CXCR4- ali dualno/mešano-tropni virus).
CXCR4-using virus was detected at failure in approximately 60% of subjects who failed treatment on maraviroc, as compared to 6% of subjects who experienced treatment failure in the placebo + OBT arm.
Ob neuspehu terapije so virus uporabnik CXCR4 ugotovili pri približno 60 % preiskovancev, pri katerih zdravljenje z maravirokom ni bilo uspešno, in pri 6 % preiskovancev, pri katerih se je neuspeh zdravljenja pojavil v kraku s placebom + OOT.
CY-2415 Έγκωμη, Λευκωσία Τηλ: +357-22-591918
CY-2415 Έγκωμη, Λευκωσία
Cyanide-poisoned patients
Bolniki, zastrupljeni s cianidom
Cyanokit 2.5 g powder for solution for infusion Hydroxocobalamin
Cyanokit 2,5 g prašek za raztopino za infundiranje hidroksokobalamin
Cyanokit 5 g powder for solution for infusion Hydroxocobalamin
Cyanokit 5 g prašek za raztopino za infundiranje hidroksokobalamin
Cyanokit may interfere with the assessment as it causes red coloration of the skin. haemodialysis.
Zdravilo Cyanokit lahko vpliva na oceno, saj povzroča rdeče obarvanje kože. hemodializo.